Transplantation Pathology of the Liver

Surgical Pathology of the GI Tract, Liver, Biliary Tract and Pancreas

Volumn , Issue , 2009, Pages 1169-1229

  Demetris, A J ^a,b   Crawford, James M ^c   Minervini, Marta Ida ^a,d   Nalesnik, Mike ^a,b   Ochoa, Erin ^b   Randhawa, Parmjeet ^a,b   Sasatomi, Eizaburo ^a   Wu, Tong ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d MEDITERRANEAN INSTITUTE FOR TRANSPLANTATION AND ADVANCED SPECIALIZED THERAPIES ISMETT   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84874705014     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-141604059-0.50047-3     Document Type: Chapter

References (495)

1. Starzl TE History of liver and other splanchnic organ transplantation. Transplantation of the Liver 1996, 3-978. WB Saunders, Philadelphia. R. Busuttil, G. Klintmalm (Eds.).
2. Klintmalm G, Busuttil R Transplantation of the Liver 1996, WB Saunders, Philadelphia.
3. Demetris AJ, Ruppert K, Dvorchik I, et al. Real-time monitoring of acute liver-allograft rejection using the Banff schema. Transplantation 2002, 74:1290-1296.
4. Jain A, Reyes J, Kashyap R, et al. Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg 2000, 232:490-500.
5. Sieders E, Peeters PM, TenVergert EM, et al. Graft loss after pediatric liver transplantation. Ann Surg 2002, 235:125-132.
6. Demetris AJ, Murase N, Nakamura K, et al. Immunopathology of antibodies as effectors of orthotopic liver allograft rejection. Semin Liver Dis 1992, 12:51-59.
7. Rabkin JM, de La Melena V, Orloff SL, et al. Late mortality after orthotopic liver transplantation. Am J Surg 2001, 181:475-479.
8. McCashland T, Watt K, Lyden E, et al. Retransplantation for hepatitis C: Results of a U.S. multicenter retransplant study. Liver Transpl 2007, 13:1246-1253.
9. Jain A, Demetris AJ, Kashyap R, et al. Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1,048 liver transplantations with a mean follow-up of 6 years. Liver Transpl 2001, 7:623-630.
10. Demetris AJ, Jaffe R, Starzl TE A review of adult and pediatric post-transplant liver pathology. Pathol Annu 1987, 22:347-386.
11. Todo S, Demetris AJ, Makowka L, et al. Primary nonfunction of hepatic allografts with preexisting fatty infiltration. Transplantation 1989, 47:903-905.
12. Kakizoe S, Yanaga K, Starzl TE, Demetris AJ Frozen section of liver biopsy for the evaluation of liver allografts. Transplant Proc 1990, 22:416-417.
13. Kakizoe S, Yanaga K, Starzl TE, Demetris AJ Evaluation of protocol before transplantation and after reperfusion biopsies from human orthotopic liver allografts: Considerations of preservation and early immunological injury. Hepatology 1990, 11:932-941.
14. Zamboni F, Franchello A, David E, et al. Effect of macro-vesicular steatosis and other donor and recipient characteristics on the outcome of liver transplantation. Clin Transplant 2001, 15:53-57.
15. Alkofer B, Samstein B, Guarrera JV, et al. Extended-donor criteria liver allografts. Semin Liver Dis 2006, 26:221-233.
16. Busuttil RW, Tanaka K The utility of marginal donors in liver transplantation. Liver Transpl 2003, 9:651-663.
17. Feng S, Goodrich NP, Bragg-Gresham JL, et al. Characteristics associated with liver graft failure: The concept of a donor risk index. Am J Transplant 2006, 6:783-790.
18. Markin RS, Wisecarver JL, Radio SJ, et al. Frozen section evaluation of donor livers before transplantation. Transplantation 1993, 56:1403-1409.
19. D'Alessandro AM, Kalayoglu M, Sollinger HW, et al. The predictive value of donor liver biopsies for the development of primary nonfunction after orthotopic liver transplantation. Transplantation 1991, 51:157-163.
20. Fiorini RN, Kirtz J, Periyasamy B, et al. Development of an unbiased method for the estimation of liver steatosis. Clin Transplant 2004, 18:700-706.
21. Testa G, Goldstein RM, Netto G, et al. Long-term outcome of patients transplanted with livers from hepatitis C-positive donors. Transplantation 1998, 65:925-929.
22. Velidedeoglu E, Desai NM, Campos L, et al. The outcome of liver grafts procured from hepatitis C-positive donors. Transplantation 2002, 73:582-587.
23. Dodson SF, Issa S, Araya V, et al. Infectivity of hepatic allografts with antibodies to hepatitis B virus. Transplantation 1997, 64:1582-1584.
24. Pungpapong S, Krishna M, Abraham SC, et al. Clinicopathologic findings and outcomes of liver transplantation using grafts from donors with unrecognized and unusual diseases. Liver Transpl 2006, 12:310-315.
25. Marcos A, Fisher RA, Ham JM, et al. Selection and outcome of living donors for adult to adult right lobe transplantation. Transplantation 2000, 69:2410-2415.
26. Shimada M, Shiotani S, Ninomiya M, et al. Characteristics of liver grafts in living-donor adult liver transplantation: Comparison between right- and left-lobe grafts. Arch Surg 2002, 137:1174-1179.
27. Trotter JF, Wachs M, Everson GT, Kam I Adult-to-adult transplantation of the right hepatic lobe from a living donor. N Engl J Med 2002, 346:1074-1082.
28. Nadalin S, Malago M, Valentin-Gamazo C, et al. Preoperative donor liver biopsy for adult living donor liver transplantation: Risks and benefits. Liver Transpl 2005, 11:980-986.
29. Tran TT, Changsri C, Shackleton CR, et al. Living donor liver transplantation: Histological abnormalities found on liver biopsies of apparently healthy potential donors. J Gastroenterol Hepatol 2006, 21:381-383.
30. Ryan CK, Johnson LA, Germin BI, Marcos A One hundred consecutive hepatic biopsies in the workup of living donors for right lobe liver transplantation. Liver Transpl 2002, 8:1114-1122.
31. Ghobrial RM, Busuttil RW Challenges of adult living-donor liver transplantation. J Hepatobiliary Pancreat Surg 2006, 13:139-145.
32. Astarcioglu I, Cursio R, Reynes M, Gugenheim J Increased risk of antibody-mediated rejection of reduced-size liver allografts. J Surg Res 1999, 87:258-262.
33. Takada Y, Taniguchi H, Fukunaga K, et al. Prolonged hepatic warm ischemia in non-heart-beating donors: Protective effects of FK506 and a platelet activating factor antagonist in porcine liver transplantation. Surgery 1998, 123:692-698.
34. Kootstra G, Kievit J, Nederstigt A Organ donors: Heartbeating and non-heartbeating. World J Surg 2002, 26:181-184.
35. Selzner N, Rudiger H, Graf R, Clavien PA Protective strategies against ischemic injury of the liver. Gastroenterology 2003, 125:917-936.
36. Teoh NC, Farrell GC Hepatic ischemia reperfusion injury: Pathogenic mechanisms and basis for hepatoprotection. J Gastroenterol Hepatol 2003, 18:891-902.
37. Kukan M, Haddad PS Role of hepatocytes and bile duct cells in preservation-reperfusion injury of liver grafts. Liver Transpl 2001, 7:381-400.
38. Bilzer M, Gerbes AL Preservation injury of the liver: Mechanisms and novel therapeutic strategies. J Hepatol 2000, 32:508-515.
39. Lichtman SN, Lemasters JJ Role of cytokines and cytokine-producing cells in reperfusion injury to the liver. Semin Liver Dis 1999, 19(2):171-187.
40. Carrasco L, Sanchez-Bueno F, Sola J, et al. Effects of cold ischemia time on the graft after orthotopic liver transplantation: A bile cytological study. Transplantation 1996, 61:393-396.
41. McDonald V, Matalon TA, Patel SK, et al. Biliary strictures in hepatic transplantation. J Vasc Interv Radiol 1991, 2:533-538.
42. Demetris AJ, Fontes P, Lunz JG, et al. Wound healing in the biliary tree of liver allografts. Cell Transplant 2006, 15(Suppl 1):S57-S65.
43. Demetris AJ, Lunz JG, Specht S, Nozaki I Biliary wound healing, ductular reactions, and IL-6/gp130 signaling in the development of liver disease. World J Gastroenterol 2006, 12:3512-3522.
44. Pirenne J, Gunson B, Khaleef H, et al. Influence of ischemia-reperfusion injury on rejection after liver transplantation. Transplant Proc 1997, 29:366-367.
45. Starzl TE, Demetris AJ Liver transplantation: A 31-year perspective: I. Curr Probl Surg 1990, 27:55-116.
46. Starzl TE, Demetris AJ Liver transplantation: A 31-year perspective: II. Curr Probl Surg 1990, 27:123-178.
47. Starzl TE, Demetris AJ Liver transplantation: A 31-year perspective: III. Curr Probl Surg 1990, 27:187-240.
48. D'Alessandro AM, Kalayoglu M, Sollinger HW, et al. The predictive value of donor liver biopsies on the development of primary nonfunction after orthotopic liver transplantation. Transplant Proc 1991, 23:1536-1537.
49. Lo CM, Fan ST, Chan JK, et al. Minimum graft volume for successful adult-to-adult living donor liver transplantation for fulminant hepatic failure. Transplantation 1996, 62:696-698.
50. Kiuchi T, Kasahara M, Uryuhara K, et al. Impact of graft size mismatching on graft prognosis in liver transplantation from living donors. Transplantation 1999, 67:321-327.
51. Nishizaki T, Ikegami T, Hiroshige S, et al. Small graft for living donor liver transplantation. Ann Surg 2001, 233:575-580.
52. Demetris AJ, Kelly DM, Eghtesad B, et al. Pathophysiologic observations and histopathologic recognition of the portal hyperperfusion or small-for-size syndrome. Am J Surg Pathol 2006, 30:986-993.
53. Marcos A, Orloff M, Mieles L, et al. Functional venous anatomy for right-lobe grafting and techniques to optimize outflow. Liver Transpl 2001, 7:845-852.
54. Marcos A, Olzinski AT, Ham JM, et al. The interrelationship between portal and arterial blood flow after adult to adult living donor liver transplantation. Transplantation 2000, 70:1697-1703.
55. Smyrniotis V, Kostopanagiotou G, Kondi A, et al. Hemodynamic interaction between portal vein and hepatic artery flow in small-for-size split liver transplantation. Transpl Int 2002, 15:355-360.
56. Lautt WW Mechanism and role of intrinsic regulation of hepatic arterial blood flow: Hepatic arterial buffer response. Am J Physiol 1985, 249:G549-G556.
57. Kelly DM, Demetris AJ, Fung JJ, et al. Porcine partial liver transplantation: A novel model of the "small-for-size" liver graft. Liver Transpl 2004, 10:253-263.
58. Man K, Lo CM, Ng IO, et al. Liver transplantation in rats using small-for-size grafts: A study of hemodynamic and morphological changes. Arch Surg 2001, 136:280-285.
59. Liang TB, Man K, Kin-Wah Lee T, et al. Distinct intragraft response pattern in relation to graft size in liver transplantation. Transplantation 2003, 75:673-678.
60. Asakura T, Ohkohchi N, Orii T, et al. Portal vein pressure is the key for successful liver transplantation of an extremely small graft in the pig model. Transpl Int 2003, 16:376-382.
61. Ayata G, Pomfret E, Pomposelli JJ, et al. Adult-to-adult live donor liver transplantation: A short-term clinicopathologic study. Hum Pathol 2001, 32:814-822.
62. Shimamura T, Taniguchi M, Jin MB, et al. Excessive portal venous inflow as a cause of allograft dysfunction in small-for-size living donor liver transplantation. Transplant Proc 2001, 33:1331.
63. Troisi R, Cammu G, Militerno G, et al. Modulation of portal graft inflow: A necessity in adult living-donor liver transplantation?. Ann Surg 2003, 237:429-436.
64. Ku Y, Fukumoto T, Nishida T, et al. Evidence that portal vein decompression improves survival of canine quarter orthotopic liver transplantation. Transplantation 1995, 59:1388-1392.
65. Boillot O, Delafosse B, Mechet I, et al. Small-for-size partial liver graft in an adult recipient: A new transplant technique. Lancet 2002, 359:406-407.
66. Man K, Fan ST, Lo CM, et al. Graft injury in relation to graft size in right lobe live donor liver transplantation: A study of hepatic sinusoidal injury in correlation with portal hemodynamics and intragraft gene expression. Ann Surg 2003, 237:256-264.
67. Pantanowitz L, Pomfret EA, Pomposelli JJ, et al. Pathologic analysis of right-lobe graft failure in adult-to-adult live donor liver transplantation. Int J Surg Pathol 2003, 11:283-294.
68. Lerut JP, Gordon RD, Tzakis AG, et al. The hepatic artery in orthotopic liver transplantation. Helv Chir Acta 1988, 55:367-378.
69. Ludwig J, Batts KP, MacCarty RL Ischemic cholangitis in hepatic allografts. Mayo Clin Proc 1992, 67:519-526.
70. Cameron AM, Busuttil RW Ischemic cholangiopathy after liver transplantation. Hepatobiliary Pancreat Dis Int 2005, 4:495-501.
71. Backman L, Gibbs J, Levy M, et al. Causes of late graft loss after liver transplantation. Transplantation 1993, 55:1078-1082.
72. Demetris A, Kakizoe S Pathology of liver transplantation. Hepatic Transplantation 1990, 61-9889. WB Saunders, Philadelphia. J.W. Williams (Ed.).
73. Lerut J, Tzakis AG, Bron K, et al. Complications of venous reconstruction in human orthotopic liver transplantation. Ann Surg 1987, 205:404-414.
74. Kuang AA, Renz JF, Ferrell LD, et al. Failure patterns of cryopreserved vein grafts in liver transplantation. Transplantation 1996, 62:742-747.
75. Sebagh M, Debette M, Samuel D, et al. "Silent" presentation of veno-occlusive disease after liver transplantation as part of the process of cellular rejection with endothelial predilection. Hepatology 1999, 30:1144-1150.
76. Wanless I Physioanatomic considerations. Diseases of the Liver 1999, 3-963. Lippincott Williams and Wilkins, Philadelphia. 8th ed. E.R. Schiff, M.F. Sorrell, W.C. Maddrey (Eds.).
77. Demetris A, Crawford J, Nalesnik M, et al. Transplantation pathology of the liver. Surgical Pathology of the GI Tract, Liver, Biliary Tract, and Pancreas 2004, 909-9034. WB Saunders, Philadelphia. R. Odze, J. Goldblum, J.M. Crawford (Eds.).
78. Demetris AJ Ischemic cholangitis [editorial; comment]. Mayo Clin Proc 1992, 67:601-602.
79. Ludwig J, Batts KP, MacCarty RL Ischemic cholangitis in hepatic allografts [see comments]. Mayo Clin Proc 1992, 67:519-526.
80. Pirenne J, Van Gelder F, Coosemans W, et al. Type of donor aortic preservation solution and not cold ischemia time is a major determinant of biliary strictures after liver transplantation. Liver Transpl 2001, 7:540-545.
81. Minor T, Hachenberg A, Tolba R, et al. Fibrinolytic preflush upon liver retrieval from non-heart beating donors to enhance postpreservation viability and energetic recovery upon reperfusion. Transplantation 2001, 71:1792-1796.
82. Testa G, Malago M, Broelseh CE Complications of biliary tract in liver transplantation. World J Surg 2001, 25:1296-1299.
83. Cheng YF, Chen YS, Huang TL, et al. Biliary complications in living related liver transplantation. Chang Gung Med J 2001, 24:174-180.
84. Amersi F, Farmer DG, Busuttil RW Fifteen-year experience with adult and pediatric liver transplantation at the University of California, Los Angeles. Clin Transpl 1998, 255-261.
85. Pascher A, Neuhaus P Bile duct complications after liver transplantation. Transpl Int 2005, 18:627-642.
86. Verdonk RC, Buis CI, Porte RJ, Haagsma EB Biliary complications after liver transplantation: A review. Scand J Gastroenterol Suppl 2006, (243):89-101.
87. Verdonk RC, Buis CI, Porte RJ, et al. Anastomotic biliary strictures after liver transplantation: Causes and consequences. Liver Transpl 2006, 12:726-735.
88. Verdonk RC, Buis CI, van der Jagt EJ, et al. Nonanastomotic biliary strictures after liver transplantation: II. Management, outcome, and risk factors for disease progression. Liver Transpl 2007, 13:725-732.
89. Buis CI, Verdonk RC, Van der Jagt EJ, et al. Nonanastomotic biliary strictures after liver transplantation: I. Radiological features and risk factors for early vs. late presentation. Liver Transpl 2007, 13:708-718.
90. Foley DP, Fernandez LA, Leverson G, et al. Donation after cardiac death: The University of Wisconsin experience with liver transplantation. Ann Surg 2005, 242:724-731.
91. Hartshorne N, Hartman G, Markin RS, et al. Bile duct hemorrhage: A biopsy finding after cholangiography or biliary tree manipulation. Liver 1992, 12:137-139.
92. Nagral A, Ben-Ari Z, Dhillon AP, Burroughs AK Eosinophils in acute cellular rejection in liver allografts. Liver Transpl Surg 1998, 4:355-362.
93. Lunz JG, Contrucci S, Ruppert K, et al. Replicative senescence of biliary epithelial cells precedes bile duct loss in chronic liver allograft rejection: Increased expression of p21(WAF1/Cip1) as a disease marker and the influence of immunosuppressive drugs. Am J Pathol 2001, 158:1379-1390.
94. Pappo O, Ramos H, Starzl TE, et al. Structural integrity and identification of causes of liver allograft dysfunction occurring more than 5 years after transplantation. Am J Surg Pathol 1995, 19:192-206.
95. Demetris AJ Distinguishing between recurrent primary sclerosing cholangitis and chronic rejection. Liver Transpl 2006, 12(11 Suppl 2):S68-S72.
96. Neuberger J Incidence, timing, and risk factors for acute and chronic rejection. Liver Transpl Surg 1999, 5(4 Suppl 1):S30-S36.
97. Terminology of chronic hepatitis, hepatic allograft rejection, and nodular lesions of the liver Summary of recommendations developed by an international working party, supported by the World Congresses of Gastroenterology, Los Angeles, 1994. Am J Gastroenterol 1994, 89(8 Suppl):S177-S181.
98. Wilson CH, Agarwal K, Carter V, et al. Late humoral rejection in a compliant ABO-compatible liver transplant recipient. Transplantation 2006, 82:988-989.
99. Demetris AJ Ischemic cholangitis. Mayo Clin Proc 1992, 67:601-602.
100. Batts KP Ischemic cholangitis. Mayo Clin Proc 1998, 73:380-385.
101. Takakura K, Kiuchi T, Kasahara M, et al. Clinical implications of flow cytometry crossmatch with T or B cells in living donor liver transplantation. Clin Transplant 2001, 15:309-316.
102. Furuya T, Murase N, Nakamura K, et al. Preformed lymphocytotoxic antibodies: The effects of class, titer and specificity on liver vs. heart allografts. Hepatology 1992, 16:1415-1422.
103. Demetris AJ, Markus BH Immunopathology of liver transplantation. Crit Rev Immunol 1989, 9:67-92.
104. Valdivia LA, Fung JJ, Demetris AJ, et al. Donor species complement after liver xenotransplantation: The mechanism of protection from hyperacute rejection. Transplantation 1994, 57:918-922.
105. Manez R, Kelly RH, Kobayashi M, et al. Immunoglobulin G lymphocytotoxic antibodies in clinical liver transplantation: Studies toward further defining their significance. Hepatology 1995, 21:1345-1352.
106. Tan CD, Baldwin WM, Rodriguez ER Update on cardiac transplantation pathology. Arch Pathol Lab Med 2007, 131:1169-1191.
107. Colvin RB Antibody-mediated renal allograft rejection: Diagnosis and pathogenesis. J Am Soc Nephrol 2007, 18:1046-1056.
108. Bellamy CO, Herriot MM, Harrison DJ, Bathgate AJ C4d immunopositivity is uncommon in ABO-compatible liver allografts but correlates partially with lymphocytotoxic antibody status. Histopathology 2007, 50:739-749.
109. Bu X, Zheng Z, Yu Y, et al. Significance of C4d deposition in the diagnosis of rejection after liver transplantation. Transplant Proc 2006, 38:1418-1421.
110. Dankof A, Schmeding M, Morawietz L, et al. Portal capillary C4d deposits and increased infiltration by macrophages indicate humorally mediated mechanisms in acute cellular liver allograft rejection. Virchows Arch 2005, 447:87-93.
111. Haga H, Egawa H, Fujimoto Y, et al. Acute humoral rejection and C4d immunostaining in ABO blood type-incompatible liver transplantation. Liver Transpl 2006, 12:457-464.
112. Jain A, Mohanka R, Orloff M, et al. Characterization of CD4, CD8, CD56 positive lymphocytes and C4d deposits to distinguish acute cellular rejection from recurrent hepatitis C in post-liver transplant biopsies. Clin Transplant 2006, 20:624-633.
113. Krukemeyer MG, Moeller J, Morawietz L, et al. Description of B lymphocytes and plasma cells, complement, and chemokines/receptors in acute liver allograft rejection. Transplantation 2004, 78:65-70.
114. Sakashita H, Haga H, Ashihara E, et al. Significance of C4d staining in ABO-identical/compatible liver transplantation. Mod Pathol 2007, 20:676-684.
115. Sawada T, Shimizu A, Kubota K, et al. Lobular damage caused by cellular and humoral immunity in liver allograft rejection. Clin Transplant 2005, 19:110-114.
116. Troxell ML, Higgins JP, Kambham N Evaluation of C4d staining in liver and small intestine allografts. Arch Pathol Lab Med 2006, 130:1489-1496.
117. Demetris AJ, Qian S, Sun H, et al. Early events in liver allograft rejection: Delineation of sites of simultaneous intragraft and recipient lymphoid tissue sensitization. Am J Pathol 1991, 138:609-618.
118. Demetris AJ, Murase N, Fujisaki S, et al. Hematolymphoid cell trafficking, microchimerism, and GVH reactions after liver, bone marrow, and heart transplantation. Transplant Proc 1993, 25:3337-3344.
119. Nawaz S, Fennell RH Apoptosis of bile duct epithelial cells in hepatic allograft rejection. Histopathology 1994, 25:137-142.
120. Vierling JM Immunology of acute and chronic hepatic allograft rejection. Liver Transpl Surg 1999, 5(4 Suppl 1):S1-S20.
121. Demetris A, Adams D, Bellamy C, et al. Update of the International Banff Schema for Liver Allograft Rejection: Working recommendations for the histopathologic staging and reporting of chronic rejection. An International Panel. Hepatology 2000, 31:792-799.
122. Terminology for hepatic allograft rejection International Working Party. Hepatology 1995, 22:648-654.
123. Seiler CA, Renner EL, Czerniak A, et al. Early acute cellular rejection: No effect on late hepatic allograft function in man. Transpl Int 1999, 12:195-201.
124. Dousset B, Conti F, Cherruau B, et al. Is acute rejection deleterious to long-term liver allograft function?. J Hepatol 1998, 29:660-668.
125. Hubscher S Diagnosis and grading of liver allograft rejection: A European perspective. Transplant Proc 1996, 28:504-507.
126. Banff schema for grading liver allograft rejection An international consensus document. Hepatology 1997, 25:658-663.
127. Yeh MM, Larson AM, Tung BY, et al. Endotheliitis in chronic viral hepatitis: A comparison with acute cellular rejection and non-alcoholic steatohepatitis. Am J Surg Pathol 2006, 30:727-733.
128. Demetris AJ, Lasky S, Van Thiel DH, et al. Induction of DR/IA antigens in human liver allografts: An immunocytochemical and clinicopathologic analysis of twenty failed grafts. Transplantation 1985, 40:504-509.
129. McCaughan GW, Davies JS, Waugh JA, et al. A quantitative analysis of T lymphocyte populations in human liver allografts undergoing rejection: The use of monoclonal antibodies and double immunolabeling. Hepatology 1990, 12:1305-1313.
130. Steinhoff G, Behrend M, Wonigeit K Expression of adhesion molecules on lymphocytes/monocytes and hepatocytes in human liver grafts. Hum Immunol 1990, 28:123-127.
131. Demetris AJ, Belle SH, Hart J, et al. Intraobserver and interobserver variation in the histopathological assessment of liver allograft rejection. The Liver Transplantation Database (LTD) Investigators. Hepatology 1991, 14:751-755.
132. Demetris AJ, Fung JJ, Todo S, et al. Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy-a clinicopathologic study of 96 patients. Transplantation 1992, 53:1056-1062.
133. Tsamandas AC, Jain AB, Felekouras ES, et al. Central venulitis in the allograft liver: A clinicopathologic study. Transplantation 1997, 64:252-257.
134. Cong WM, Zhang SY, Wang ZL, et al. [Pathologic diagnosis of 1123 post-transplant liver biopsies from 665 liver transplant patients]. Zhonghua Bing Li Xue Za Zhi 2005, 34:716-719.
135. Netto GJ, Watkins DL, Williams JW, et al. Interobserver agreement in hepatitis C grading and staging and in the Banff grading schema for acute cellular rejection: The "hepatitis C 3" multi-institutional trial experience. Arch Pathol Lab Med 2006, 130:1157-1162.
136. Demetris AJ, Adeyi O, Bellamy CO, et al. Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology 2006, 44:489-501.
137. Hubscher SG Recurrent autoimmune hepatitis after liver transplantation: Diagnostic criteria, risk factors, and out-come. Liver Transpl 2001, 7:285-291.
138. Krasinskas AM, Ruchelli ED, Rand EB, et al. Central venulitis in pediatric liver allografts. Hepatology 2001, 33:1141-1147.
139. Khettry U, Backer A, Ayata G, et al. Centrilobular histopathologic changes in liver transplant biopsies. Hum Pathol 2002, 33:270-276.
140. Demetris AJ, Eghtesad B, Marcos A, et al. Recurrent hepatitis C in liver allografts: Prospective assessment of diagnostic accuracy, identification of pitfalls, and observations about pathogenesis. Am J Surg Pathol 2004, 28:658-669.
141. Walter T, Dumortier J, Guillaud O, et al. Rejection under alpha interferon therapy in liver transplant recipients. Am J Transplant 2007, 7:177-184.
142. Stanca CM, Fiel MI, Kontorinis N, et al. Chronic ductopenic rejection in patients with recurrent hepatitis C virus treated with pegylated interferon alfa-2a and ribavirin. Transplantation 2007, 84:180-186.
143. Blakolmer K, Jain A, Ruppert K, et al. Chronic liver allograft rejection in a population treated primarily with tacrolimus as baseline immunosuppression: Long-term follow-up and evaluation of features for histopathological staging. Transplantation 2000, 69:2330-2336.
144. Evans PC, Smith S, Hirschfield G, et al. Recipient HLA-DR3, tumour necrosis factor-alpha promoter allele-2 (tumour necrosis factor-2) and cytomegalovirus infection are interrelated risk factors for chronic rejection of liver grafts. J Hepatol 2001, 34:711-715.
145. Blakolmer K, Seaberg EC, Batts K, et al. Analysis of the reversibility of chronic liver allograft rejection implications for a staging schema. Am J Surg Pathol 1999, 23:1328-1339.
146. Neil DA, Hubscher SG Histologic and biochemical changes during the evolution of chronic rejection of liver allografts. Hepatology 2002, 35:639-651.
147. Nakazawa Y, Jonsson JR, Walker NI, et al. Fibrous obliterative lesions of veins contribute to progressive fibrosis in chronic liver allograft rejection. Hepatology 2000, 32:1240-1247.
148. Oguma S, Belle S, Starzl TE, Demetris AJ A histometric analysis of chronically rejected human liver allografts: Insights into the mechanisms of bile duct loss: direct immunologic and ischemic factors. Hepatology 1989, 9:204-209.
149. Matsumoto Y, McCaughan GW, Painter DM, Bishop GA Evidence that portal tract microvascular destruction precedes bile duct loss in human liver allograft rejection. Transplantation 1993, 56:69-75.
150. Hubscher SG, Buckels JA, Elias E, et al. Vanishing bile-duct syndrome following liver transplantation-is it reversible?. Transplantation 1991, 51:1004-1010.
151. van den Heuvel MC, de Jong KP, Boot M, et al. Preservation of bile ductules mitigates bile duct loss. Am J Transplant 2006, 6:2660-2671.
152. Demetris AJ, Seaberg EC, Batts KP, et al. Chronic liver allograft rejection: A National Institute of Diabetes and Digestive and Kidney Diseases interinstitutional study analyzing the reliability of current criteria and proposal of an expanded definition. National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Am J Surg Pathol 1998, 22:28-39.
153. White RM, Zajko AB, Demetris AJ, et al. Liver transplant rejection: Angiographic findings in 35 patients. AJR Am J Roentgenol 1987, 148:1095-1098.
154. O'Keeffe C, Baird AW, Nolan N, McCormick PA Mast cell hyperplasia in chronic rejection after liver transplantation. Liver Transpl 2002, 8:50-57.
155. Crawford AR, Lin XZ, Crawford JM The normal adult human liver biopsy: A quantitative reference standard. Hepatology 1998, 28:323-331.
156. Freese DK, Snover DC, Sharp HL, et al. Chronic rejection after liver transplantation: A study of clinical, histopathological and immunological features. Hepatology 1991, 13:882-891.
157. Quaglia AF, Del Vecchio Blanco G, Greaves R, et al. Development of ductopaenic liver allograft rejection includes a "hepatitic" phase prior to duct loss. J Hepatol 2000, 33:773-780.
158. Pathology of the Liver 2002, 982. Churchill Livingstone, Philadelphia. 4th ed. R.N. MacSween, A.D. Burt, B. Portmann (Eds.).
159. Bai X, Rogers BB, Harkins PC, et al. Predictive value of quantitative PCR-based viral burden analysis for eight human herpesviruses in pediatric solid organ transplant patients. J Mol Diagn 2000, 2:191-201.
160. Badley AD, Seaberg EC, Porayko MK, et al. Prophylaxis of cytomegalovirus infection in liver transplantation: A randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. NIDDK Liver Transplantation Database. Transplantation 1997, 64:66-73.
161. Barkholt L, Lewensohn-Fuchs I, Ericzon BG, et al. High-dose acyclovir prophylaxis reduces cytomegalovirus disease in liver transplant patients. Transpl Infect Dis 1999, 1:89-97.
162. McGavin JK, Goa KL Ganciclovir: An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs 2001, 61:1153-1183.
163. Theise ND, Conn M, Thung SN Localization of cytomegalovirus antigens in liver allografts over time. Hum Pathol 1993, 24:103-108.
164. Bronsther O, Makowka L, Jaffe R, et al. Occurrence of cytomegalovirus hepatitis in liver transplant patients. J Med Virol 1988, 24:423-434.
165. Snover DC, Hutton S, Balfour HH, Bloomer JR Cytomegalovirus infection of the liver in transplant recipients. J Clin Gastroenterol 1987, 9:659-665.
166. Wiesner RH, Marin E, Porayko MK, et al. Advances in the diagnosis, treatment, and prevention of cytomegalovirus infections after liver transplantation. Gastroenterol Clin North Am 1993, 22:351-366.
167. Toorkey CB, Carrigan DR Immunohistochemical detection of an immediate early antigen of human cytomegalovirus in normal tissues. J Infect Dis 1989, 160:741-751.
168. Oh CK, Pelletier SJ, Sawyer RG, et al. Uni- and multi-variate analysis of risk factors for early and late hepatic artery thrombosis after liver transplantation. Transplantation 2001, 71:767-772.
169. Pastacaldi S, Teixeira R, Montalto P, et al. Hepatic artery thrombosis after orthotopic liver transplantation: A review of nonsurgical causes. Liver Transpl 2001, 7:75-81.
170. Lautenschlager I, Halme L, Hockerstedt K, et al. Cytomegalovirus infection of the liver transplant: Virological, histological, immunological, and clinical observations. Transpl Infect Dis 2006, 8:21-30.
171. Charlton M, Wiesner R Natural history and management of hepatitis C infection after liver transplantation. Semin Liver Dis 2004, 24(Suppl 2):79-88.
172. Demetris A, Tsamandas A, Delaney CP, et al. Pathology of liver transplantation. Transplantation of the Liver 1996, 681-9277. WB Saunders, Philadelphia. R. Busuttil, G. Klintmalm (Eds.).
173. O'Grady JG, Alexander GJ, Sutherland S, et al. Cytomegalovirus infection and donor/recipient HLA antigens: Interdependent co-factors in pathogenesis of vanishing bile-duct syndrome after liver transplantation. Lancet 1988, 2:302-305.
174. Lautenschlager I, Hockerstedt K, Jalanko H, et al. Persistent cytomegalovirus in liver allografts with chronic rejection. Hepatology 1997, 25:190-194.
175. Paya CV, Wiesner RH, Hermans PE, et al. Lack of association between cytomegalovirus infection, HLA matching and the vanishing bile duct syndrome after liver transplantation. Hepatology 1992, 16:66-70.
176. Kusne S, Schwartz M, Breinig MK, et al. Herpes simplex virus hepatitis after solid organ transplantation in adults. J Infect Dis 1991, 163:1001-1007.
177. Snow AL, Martinez OM Epstein-Barr virus: Evasive maneuvers in the development of PTLD. Am J Transplant 2007, 7:271-277.
178. Nalesnik MA Clinicopathologic characteristics of post-transplant lymphoproliferative disorders. Recent Results Cancer Res 2002, 159:9-18.
179. Nalesnik MA The diverse pathology of post-transplant lymphoproliferative disorders: The importance of a standardized approach. Transpl Infect Dis 2001, 3:88-96.
180. Bakker NA, van Imhoff GW, Verschuuren EA, van Son WJ Presentation and early detection of post-transplant lymphoproliferative disorder after solid organ transplantation. Transpl Int 2007, 20:207-218.
181. Randhawa PS, Markin RS, Starzl TE, Demetris AJ Epstein-Barr virus-associated syndromes in immunosuppressed liver transplant recipients: Clinical profile and recognition on routine allograft biopsy. Am J Surg Pathol 1990, 14:538-547.
182. Randhawa PS, Jaffe R, Demetris AJ, et al. The systemic distribution of Epstein-Barr virus genomes in fatal post-transplantation lymphoproliferative disorders: An in situ hybridization study. Am J Pathol 1991, 138:1027-1033.
183. Randhawa PS, Jaffe R, Demetris AJ, et al. Expression of Epstein-Barr virus-encoded small RNA (by the EBER-1 gene) in liver specimens from transplant recipients with post-transplantation lymphoproliferative disease. N Engl J Med 1992, 327:1710-1714.
184. Nalesnik MA, Jaffe R, Starzl TE, et al. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A/prednisone immunosuppression. Am J Pathol 1988, 133:173-192.
185. Bierman PJ, Vose JM, Langnas AN, et al. Hodgkin's disease following solid organ transplantation. Ann Oncol 1996, 7:265-270.
186. Sivaraman P, Lye WC Epstein-Barr virus-associated T-cell lymphoma in solid organ transplant recipients. Biomed Pharmacother 2001, 55:366-368.
187. Lee ES, Locker J, Nalesnik M, et al. The association of Epstein-Barr virus with smooth-muscle tumors occurring after organ transplantation. N Engl J Med 1995, 332:19-25.
188. Newell KA, Alonso EM, Whitington PF, et al. Posttransplant lymphoproliferative disease in pediatric liver transplantation:
189. Manez R, Breinig MC, Linden P, et al. Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: The role of cytomegalovirus disease. J Infect Dis 1997, 176:1462-1467.
190. Cockfield SM Identifying the patient at risk for post-transplant lymphoproliferative disorder. Transpl Infect Dis 2001, 3:70-78.
191. Randhawa P, Blakolmer K, Kashyap R, et al. Allograft liver biopsy in patients with Epstein-Barr virus-associated posttransplant lymphoproliferative disease. Am J Surg Pathol 2001, 25:324-330.
192. Hubscher SG, Williams A, Davison SM, et al. Epstein-Barr virus in inflammatory diseases of the liver and liver allografts: An in situ hybridization study. Hepatology 1994, 20:899-907.
193. Muti G, Cantoni S, Oreste P, et al. Post-transplant lymphoproliferative disorders: Improved outcome after clinico-pathologically tailored treatment. Haematologica 2002, 87:67-77.
194. Koneru B, Jaffe R, Esquivel CO, et al. Adenoviral infections in pediatric liver transplant recipients. JAMA 1987, 258:489-492.
195. Michaels MG, Green M, Wald ER, Starzl TE Adenovirus infection in pediatric liver transplant recipients. J Infect Dis 1992, 165:170-174.
196. Saad RS, Demetris AJ, Lee RG, et al. Adenovirus hepatitis in the adult allograft liver. Transplantation 1997, 64:1483-1485.
197. McGrath D, Falagas ME, Freeman R, et al. Adenovirus infection in adult orthotopic liver transplant recipients: Incidence and clinical significance. J Infect Dis 1998, 177:459-462.
198. Berenguer M, Rayon JM, Prieto M, et al. Are posttransplantation protocol liver biopsies useful in the long term?. Liver Transpl 2001, 7:790-796.
199. Burra P, Mioni D, Cecchetto A, et al. Histological features after liver transplantation in alcoholic cirrhotics. J Hepatol 2001, 34:716-722.
200. Berenguer M, Aguilera V, Prieto M, et al. Delayed onset of severe hepatitis C-related liver damage following liver transplantation: A matter of concern?. Liver Transpl 2003, 9:1152-1158.
201. Sebagh M, Rifai K, Feray C, et al. All liver recipients benefit from the protocol 10-year liver biopsies. Hepatology 2003, 37:1293-1301.
202. Slapak GI, Saxena R, Portmann B, et al. Graft and systemic disease in long-term survivors of liver transplantation. Hepatology 1997, 25:195-202.
203. Rosenthal P, Emond JC, Heyman MB, et al. Pathological changes in yearly protocol liver biopsy specimens from healthy pediatric liver recipients. Liver Transpl Surg 1997, 3:559-562.
204. Wong T, Nouri-Aria KT, Devlin J, et al. Tolerance and latent cellular rejection in long-term liver transplant recipients. Hepatology 1998, 28:443-449.
205. Gane E, Portmann B, Saxena R, et al. Nodular regenerative hyperplasia of the liver graft after liver transplantation. Hepatology 1994, 20:88-94.
206. Dubel L, Farges O, Johanet C, et al. High incidence of antitissue antibodies in patients experiencing chronic liver allograft rejection. Transplantation 1998, 65:1072-1075.
207. Duclos-Vallee JC, Johanet C, Bach JF, Yamamoto AM Autoantibodies associated with acute rejection after liver transplantation for type-2 autoimmune hepatitis. J Hepatol 2000, 33:163-166.
208. Shinkura N, Ikai I, Egawa H, et al. Presence of anti-FKBP12 autoantibodies in patients with liver allografts: Its association with allograft rejection. Transplantation 1997, 64(9):1336-1342.
209. Salcedo M, Vaquero J, Banares R, et al. Response to steroids in de novo autoimmune hepatitis after liver transplantation. Hepatology 2002, 35:349-356.
210. Gupta P, Hart J, Millis JM, et al. De novo hepatitis with autoimmune antibodies and atypical histology: A rare cause of late graft dysfunction after pediatric liver transplantation. Transplantation 2001, 71:664-668.
211. Heneghan MA, Portmann BC, Norris SM, et al. Graft dysfunction mimicking autoimmune hepatitis following liver transplantation in adults. Hepatology 2001, 34:464-470.
212. Hernandez HM, Kovarik P, Whitington PF, Alonso EM Autoimmune hepatitis as a late complication of liver transplantation. J Pediatr Gastroenterol Nutr 2001, 32:131-136.
213. Aguilera I, Wichmann I, Sousa JM, et al. Antibodies against glutathione S-transferase T1 (GSTT1) in patients with de novo immune hepatitis following liver transplantation. Clin Exp Immunol 2001, 126:535-539.
214. Jones DE, James OF, Portmann B, et al. Development of autoimmune hepatitis following liver transplantation for primary biliary cirrhosis. Hepatology 1999, 30:53-57.
215. Kerkar N, Hadzic N, Davies ET, et al. De-novo autoimmune hepatitis after liver transplantation. Lancet 1998, 351:409-413.
216. Iwatsuki S, Gordon RD, Shaw BW, Starzl TE Role of liver transplantation in cancer therapy. Ann Surg 1985, 202:401-407.
217. Iwatsuki S, Starzl TE, Sheahan DG, et al. Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg 1991, 214:221-228.
218. Iwatsuki S, Starzl TE Role of liver transplantation in the treatment of hepatocellular carcinoma. Semin Surg Oncol 1993, 9:337-340.
219. Hunt J, Gordon FD, Jenkins RL, et al. Sarcoidosis with selective involvement of a second liver allograft: Report of a case and review of the literature. Mod Pathol 1999, 12:325-328.
220. Pappo O, Yunis E, Jordan JA, et al. Recurrent and de novo giant cell hepatitis after orthotopic liver transplantation. Am J Surg Pathol 1994, 18:804-813.
221. Cavallari A, De Raffele E, Bellusci R, et al. De novo hepatitis B and C viral infection after liver transplantation. World J Surg 1997, 21:78-84.
222. Fagan E, Yousef G, Brahm J, et al. Persistence of hepatitis A virus in fulminant hepatitis and after liver transplantation. J Med Virol 1990, 30:131-136.
223. Huang J Ethical and legislative perspectives on liver transplantation in the People's Republic of China. Liver Transpl 2007, 13:193-196.
224. Zheng SS, Liang TB, Wang WL, et al. Clinical experience in liver transplantation from an organ transplantation center in China. Hepatobiliary Pancreat Dis Int 2002, 1:487-491.
225. Uemoto S, Sugiyama K, Marusawa H, et al. Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants. Transplantation 1998, 65:494-499.
226. Demetris AJ, Jaffe R, Sheahan DG, et al. Recurrent hepatitis B in liver allograft recipients: Differentiation between viral hepatitis B and rejection. Am J Pathol 1986, 125:161-172.
227. Demetris AJ, Todo S, Van Thiel DH, et al. Evolution of hepatitis B virus liver disease after hepatic replacement: Practical and theoretical considerations. Am J Pathol 1990, 137:667-676.
228. O'Grady JG, Smith HM, Davies SE, et al. Hepatitis B virus reinfection after orthotopic liver transplantation: Serological and clinical implications. J Hepatol 1992, 14:104-111.
229. Davies SE, Portmann BC, O'Grady JG, et al. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology 1991, 13:150-157.
230. Mason AL, Wick M, White HM, et al. Increased hepatocyte expression of hepatitis B virus transcription in patients with features of fibrosing cholestatic hepatitis. Gastroenterology 1993, 105:237-244.
231. Todo S, Demetris AJ, Van Thiel D, et al. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 1991, 13:619-626.
232. Samuel D, Bismuth H Liver transplantation for hepatitis B. Gastroenterol Clin North Am 1993, 22:271-283.
233. Prieto M, Gomez MD, Berenguer M, et al. De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population. Liver Transpl 2001, 7:51-58.
234. Vargas HE, Dodson FS, Rakela J A concise update on the status of liver transplantation for hepatitis B virus: The challenges in 2002. Liver Transpl 2002, 8:2-9.
235. Marzano A, Angelucci E, Andreone P, et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis 2007, 39:397-408.
236. Eisenbach C, Sauer P, Mehrabi A, et al. Prevention of hepatitis B virus recurrence after liver transplantation. Clin Transplant 2006, 20(Suppl 17):111-116.
237. Marinos G, Rossol S, Carucci P, et al. Immunopathogenesis of hepatitis B virus recurrence after liver transplantation. Transplantation 2000, 69:559-568.
238. Porter KA Pathology of liver transplantation. Transplant Rev 1969, 2:129-170.
239. Gouw AS, Houthoff HJ, Huitema S, et al. Expression of major histocompatibility complex antigens and replacement of donor cells by recipient ones in human liver grafts. Transplantation 1987, 43:291-296.
240. Thung SN Histologic findings in recurrent HBV. Liver Transpl 2006, 12(11 Suppl 2):S50-S53.
241. Phillips MJ, Cameron R, Flowers MA, et al. Post-transplant recurrent hepatitis B viral liver disease: Viral-burden, steatoviral, and fibroviral hepatitis B. Am J Pathol 1992, 140:1295-1308.
242. Benner KG, Lee RG, Keeffe EB, et al. Fibrosing cytolytic liver failure secondary to recurrent hepatitis B after liver transplantation. Gastroenterology 1992, 103:1307-1312.
243. Chisari FV, Filippi P, Buras J, et al. Structural and pathological effects of synthesis of hepatitis B virus large envelope polypeptide in transgenic mice. Proc Natl Acad Sci U S A 1987, 84:6909-6913.
244. Rizzetto M, Macagno S, Chiaberge E, et al. Liver transplantation in hepatitis delta virus disease. Lancet 1987, 2:469-471.
245. Reynes M, Zignego L, Samuel D, et al. Graft hepatitis delta virus reinfection after orthotopic liver transplantation in HDV cirrhosis. Transplant Proc 1989, 21:2424-2425.
246. David E, Rahier J, Pucci A, et al. Recurrence of hepatitis D (delta) in liver transplants: Histopathological aspects. Gastroenterology 1993, 104:1122-1128.
247. Arnold JC, Kraus T, Otto G, et al. Recurrent hepatitis C virus infection after liver transplantation. Transplant Proc 1992, 24:2646-2647.
248. Mateo R, Demetris A, Sico E, et al. Early detection of de novo hepatitis C infection in patients after liver transplantation by reverse transcriptase polymerase chain reaction. Surgery 1993, 114:442-448.
249. Marzano A, Smedile A, Abate M, et al. Hepatitis type C after orthotopic liver transplantation: Reinfection and disease recurrence. J Hepatol 1994, 21:961-965.
250. Belli LS, Silini E, Alberti A, et al. Hepatitis C virus genotypes, hepatitis, and hepatitis C virus recurrence after liver transplantation. Liver Transpl Surg 1996, 2:200-205.
251. Feray C, Gigou M, Samuel D, et al. Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation. Gastroenterology 1995, 108:1088-1096.
252. Gayowski T, Singh N, Marino IR, et al. Hepatitis C virus genotypes in liver transplant recipients: Impact on posttransplant recurrence, infections, response to interferon-alpha therapy and outcome. Transplantation 1997, 64:422-426.
253. Spengler U, Nattermann J Immunopathogenesis in hepatitis C virus cirrhosis. Clin Sci (Lond) 2007, 112:141-155.
254. McCaughan GW, Zekry A Mechanisms of HCV reinfection and allograft damage after liver transplantation. J Hepatol 2004, 40:368-374.
255. Demetris AJ, Lunz JG Early HCV-associated stellate cell activation in aggressive recurrent HCV: What can liver allografts teach about HCV pathogenesis?. Liver Transpl 2005, 11:1172-1176.
256. Zekry A, Bishop GA, Bowen DG, et al. Intrahepatic cytokine profiles associated with posttransplantation hepatitis C virus-related liver injury. Liver Transpl 2002, 8:292-301.
257. Eghtesad B, Fung JJ, Demetris AJ, et al. Immunosuppression for liver transplantation in HCV-infected patients: Mechanism-based principles. Liver Transpl 2005, 11:1343-1352.
258. Berenguer M, Aguilera V, Prieto M, et al. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. J Hepatol 2006, 44:717-722.
259. Tisone G, Orlando G, Cardillo A, et al. Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence. J Hepatol 2006, 44:702-709.
260. Khettry U, Huang WY, Simpson MA, et al. Patterns of recurrent hepatitis C after liver transplantation in a recent cohort of patients. Hum Pathol 2007, 38:443-452.
261. Dixon LR, Crawford JM Early histologic changes in fibrosing cholestatic hepatitis C. Liver Transpl 2007, 13:219-226.
262. Ferrell LD, Wright TL, Roberts J, et al. Hepatitis C viral infection in liver transplant recipients. Hepatology 1992, 16:865-876.
263. Tsamandas AC, Furukawa H, Abu-Elmagd K, et al. Liver allograft pathology in liver/small bowel or multivisceral recipients. Mod Pathol 1996, 9:767-773.
264. Russo MW, Firpi RJ, Nelson DR, et al. Early hepatic stellate cell activation is associated with advanced fibrosis after liver transplantation in recipients with hepatitis C. Liver Transpl 2005, 11:1235-1241.
265. Gawrieh S, Papouchado BG, Burgart LJ, et al. Early hepatic stellate cell activation predicts severe hepatitis C recurrence after liver transplantation. Liver Transpl 2005, 11:1207-1213.
266. Asanza CG, Garcia-Monzon C, Clemente G, et al. Immunohistochemical evidence of immunopathogenetic mechanisms in chronic hepatitis C recurrence after liver transplantation. Hepatology 1997, 26:755-763.
267. Rosen HR, Gretch DR, Oehlke M, et al. Timing and severity of initial hepatitis C recurrence as predictors of long-term liver allograft injury. Transplantation 1998, 65:1178-1182.
268. Rosen HR, Martin P Hepatitis C infection in patients undergoing liver retransplantation. Transplantation 1998, 66:1612-1616.
269. Lumbreras C, Colina F, Loinaz C, et al. Clinical, virological, and histologic evolution of hepatitis C virus infection in liver transplant recipients. Clin Infect Dis 1998, 26:48-55.
270. Charco R, Vargas V, Allende H, et al. Is hepatitis C virus recurrence a risk factor for chronic liver allograft rejection?. Transpl Int 1996, 9(Suppl 1):S195-S197.
271. Hoffmann RM, Gunther C, Diepolder HM, et al. Hepatitis C virus infection as a possible risk factor for ductopenic rejection (vanishing bile duct syndrome) after liver transplantation. Transpl Int 1995, 8:353-359.
272. Ontanon J, Muro M, Garcia-Alonso AM, et al. Effect of partial HLA class I match on acute rejection in viral pre-infected human liver allograft recipients. Transplantation 1998, 65:1047-1053.
273. Jain A, Demetris AJ, Manez R, et al. Incidence and severity of acute allograft rejection in liver transplant recipients treated with alfa interferon. Liver Transpl Surg 1998, 4:197-203.
274. Dousset B, Conti F, Houssin D, Calmus Y Acute vanishing bile duct syndrome after interferon therapy for recurrent HCV infection in liver-transplant recipients. N Engl J Med 1994, 330:1160-1161.
275. Thung SN, Shim KS, Shieh YS, et al. Hepatitis C in liver allografts. Arch Pathol Lab Med 1993, 117:145-149.
276. Wiesner RH, Demetris AJ, Belle SH, et al. Acute hepatic allograft rejection: Incidence, risk factors, and impact on outcome. Hepatology 1998, 28:638-645.
277. Burton JR, Rosen HR Acute rejection in HCV-infected liver transplant recipients: The great conundrum. Liver Transpl 2006, 12(11 Suppl 2):S38-S47.
278. Faust TW Recurrent primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis after transplantation. Liver Transpl 2001, 7(11 Suppl 1):S99-S108.
279. Gautam M, Cheruvattath R, Balan V Recurrence of autoimmune liver disease after liver transplantation: A systematic review. Liver Transpl 2006, 12:1813-1824.
280. Dmitrewski J, Hubscher SG, Mayer AD, Neuberger JM Recurrence of primary biliary cirrhosis in the liver allograft: The effect of immunosuppression. J Hepatol 1996, 24:253-257.
281. Liermann Garcia RF, Evangelista Garcia C, McMaster P, Neuberger J Transplantation for primary biliary cirrhosis: Retrospective analysis of 400 patients in a single center. Hepatology 2001, 33:22-27.
282. Hashimoto E, Shimada M, Noguchi S, et al. Disease recurrence after living liver transplantation for primary biliary cirrhosis: A clinical and histological follow-up study. Liver Transpl 2001, 7:588-595.
283. Mazariegos GV, Reyes J, Marino IR, et al. Weaning of immunosuppression in liver transplant recipients. Transplantation 1997, 63:243-249.
284. Ramos HC, Reyes J, Abu-Elmagd K, et al. Weaning of immunosuppression in long-term liver transplant recipients. Transplantation 1995, 59:212-217.
285. Charatcharoenwitthaya P, Pimentel S, Talwalkar JA, et al. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl 2007, 13:1236-1245.
286. Farges O, Bismuth H, Sebagh M, Reynes M Granulomatous destruction of bile ducts after liver transplantation: Primary biliary cirrhosis recurrence or hepatitis C virus infection?. Hepatology 1995, 21:1765-1767.
287. Hubscher SG, Elias E, Buckels JA, et al. Primary biliary cirrhosis: Histological evidence of disease recurrence after liver transplantation. J Hepatol 1993, 18:173-184.
288. Sebagh M, Farges O, Dubel L, et al. Histological features predictive of recurrence of primary biliary cirrhosis after liver transplantation. Transplantation 1998, 65:1328-1333.
289. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: Review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999, 31:929-938.
290. Demetris AJ, Murase N, Delaney CP Overlap between allo- and autoimmunity in the rat and human evidence for important contributions for dendritic and regulatory cells. Graft 2003, 6:21-32.
291. Graze PR, Gale RP Chronic graft versus host disease: A syndrome of disordered immunity. Am J Med 1979, 66:611-620.
292. Salcedo M, Vaquero J, Banares R, et al. Serum autoanti-bodies after liver transplantation: Prevalence and associated immunologic disorders [Abstract]. J Hepatol 2003, 34(Suppl 1):47.
293. Ratziu V, Samuel D, Sebagh M, et al. Long-term follow-up after liver transplantation for autoimmune hepatitis: Evidence of recurrence of primary disease. J Hepatol 1999, 30:131-141.
294. Reich DJ, Fiel I, Guarrera JV, et al. Liver transplantation for autoimmune hepatitis. Hepatology 2000, 32:693-700.
295. Venick RS, McDiarmid SV, Farmer DG, et al. Rejection and steroid dependence: Unique risk factors in the development of pediatric posttransplant de novo autoimmune hepatitis. Am J Transplant 2007, 7:955-963.
296. Goss JA, Shackleton CR, Farmer DG, et al. Orthotopic liver transplantation for primary sclerosing cholangitis: A 12-year single center experience. Ann Surg 1997, 225:472-481.
297. Graziadei IW, Wiesner RH, Marotta PJ, et al. Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology 1999, 30:1121-1127.
298. Gow PJ, Chapman RW Liver transplantation for primary sclerosing cholangitis. Liver 2000, 20:97-103.
299. Dvorchik I, Subotin M, Demetris AJ, et al. Effect of liver transplantation on inflammatory bowel disease in patients with primary sclerosing cholangitis. Hepatology 2002, 35:380-384.
300. Narumi S, Roberts JP, Emond JC, et al. Liver transplantation for sclerosing cholangitis. Hepatology 1995, 22:451-457.
301. Jeyarajah DR, Netto GJ, Lee SP, et al. Recurrent primary sclerosing cholangitis after orthotopic liver transplantation: Is chronic rejection part of the disease process?. Transplantation 1998, 66:1300-1306.
302. Sheng R, Campbell WL, Zajko AB, Baron RL Cholangiographic features of biliary strictures after liver transplantation for primary sclerosing cholangitis: Evidence of recurrent disease. AJR Am J Roentgenol 1996, 166:1109-1113.
303. Harrison RF, Davies MH, Neuberger JM, Hubscher SG Fibrous and obliterative cholangitis in liver allografts: Evidence of recurrent primary sclerosing cholangitis?. Hepatology 1994, 20:356-361.
304. Jaffe R Liver transplant pathology in pediatric metabolic disorders. Pediatr Dev Pathol 1998, 1:102-117.
305. Bellamy CO, DiMartini AM, Ruppert K, et al. Liver transplantation for alcoholic cirrhosis: Long-term follow-up and impact of disease recurrence. Transplantation 2001, 72:619-626.
306. Lucey MR, Carr K, Beresford TP, et al. Alcohol use after liver transplantation in alcoholics: A clinical cohort follow-up study. Hepatology 1997, 25(5):1223-1227.
307. Osorio RW, Ascher NL, Avery M, et al. Predicting recidi-vism after orthotopic liver transplantation for alcoholic liver disease. Hepatology 1994, 20:105-110.
308. Berlakovich GA, Steininger R, Herbst F, et al. Efficacy of liver transplantation for alcoholic cirrhosis with respect to recidivism and compliance. Transplantation 1994, 58:560-565.
309. Conjeevaram HS, Hart J, Lissoos TW, et al. Rapidly progressive liver injury and fatal alcoholic hepatitis occurring after liver transplantation in alcoholic patients. Transplantation 1999, 67:1562-1568.
310. Molloy RM, Komorowski R, Varma RR Recurrent nonalcoholic steatohepatitis and cirrhosis after liver transplantation. Liver Transpl Surg 1997, 3:177-178.
311. Tang H, Boulton R, Gunson B, et al. Patterns of alcohol consumption after liver transplantation. Gut 1998, 43:140-145.
312. Yusoff IF, House AK, De Boer WB, et al. Disease recurrence after liver transplantation in Western Australia. J Gastroenterol Hepatol 2002, 17:203-207.
313. Burke A, Lucey MR Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and orthotopic liver transplantation. Am J Transplant 2004, 4:686-693.
314. Abosh D, Rosser B, Kaita K, et al. Outcomes following liver transplantation for patients with alcohol- versus nonalcohol-induced liver disease. Can J Gastroenterol 2000, 14:851-855.
315. Evans HM, Kelly DA, McKiernan PJ, Hubscher S Progressive histological damage in liver allografts following pediatric liver transplantation. Hepatology 2006, 43:1109-1117.
316. Shaikh OS, Demetris AJ Idiopathic posttransplantation hepatitis?. Liver Transpl 2007, 13:943-946.
317. Lefkowitch JH, Lobritto SJ, Brown RS, et al. Ground-glass, polyglucosan-like hepatocellular inclusions: A "new" diagnostic entity. Gastroenterology 2006, 131:713-718.
318. + regulatory T cells: Their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001, 182:18-32.
319. Koshiba T, Li Y, Takemura M, et al. Clinical, immunological, and pathological aspects of operational tolerance after pediatric living-donor liver transplantation. Transpl Immunol 2007, 17:94-97.
320. Martinez-Llordella M, Puig-Pey I, Orlando G, et al. Multiparameter immune profiling of operational tolerance in liver transplantation. Am J Transplant 2007, 7:309-319.
321. Reding R, Gras J, Bourdeaux C, et al. Stepwise minimization of the immunosuppressive therapy in pediatric liver transplantation: A conceptual approach towards operational tolerance. Acta Gastroenterol Belg 2005, 68:320-322.
322. Lerut J, Sanchez-Fueyo A An appraisal of tolerance in liver transplantation. Am J Transplant 2006, 6:1774-1780.
323. Yoshitomi M, Koshiba T, Sakashita H, et al. Requirement of protocol biopsy before and after complete cessation of immunosuppression following living-donor liver transplantation. Am J Transplant 2006, 6(Suppl 2):173.
324. Sterneck M, Wiesner R, Ascher N, et al. Azathioprine hepatotoxicity after liver transplantation. Hepatology 1991, 14:806-810.
325. McDonald GB, Shulman HM, Wolford JL, Spencer GD Liver disease after human marrow transplantation. Semin Liver Dis 1987, 7:210-229.
326. Crawford J, Ferrell L The liver in transplantation. The Liver in Systemic Diseases 1993, 337-9636. Raven Press, New York. V. Rustgi, D. Van Thiel (Eds.).
327. Shulman HM, Fisher LB, Schoch HG, et al. Veno-occlusive disease of the liver after marrow transplantation: Histological correlates of clinical signs and symptoms. Hepatology 1994, 19:1171-1181.
328. Liu C, Crawford JM Graft-versus-host disease of the liver. Graft vs. Host Disease 2004, 257-9722. Marcel Dekker, New York. 3rd ed. J.L.M. Ferrara, J. Deeg, S. Burakoff (Eds.).
329. McDonald GB, Sharma P, Matthews DE, et al. The clinical course of 53 patients with venocclusive disease of the liver after marrow transplantation. Transplantation 1985, 39:603-608.
330. Helmy A Review article: Updates in the pathogenesis and therapy of hepatic sinusoidal obstruction syndrome. Aliment Pharmacol Ther 2006, 23:11-25.
331. Bras G, Jelliffe D, Stuart K Veno-occlusive disease of liver with nonportal type of cirrhosis, occurring in Jamaica. Arch Pathol Lab Med 1954, 57:285-300.
332. McLean EK The toxic actions of pyrrolizidine (senecio) alkaloids. Pharmacol Rev 1970, 22:429-483.
333. Carreras E, Bartz H, Arcese W, et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: A prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood 1998, 118:255-267.
334. Ramasamy K, Lim ZY, Pagliuca A, et al. Incidence and management of hepatic venoocclusive disease in 237 patients undergoing reduced-intensity conditioning (RIC) haematopoietic stem cell transplantation (HSCT). Bone Marrow Transplantation 2006, 38:823-824.
335. Ferrara JL, Reddy P Pathophysiology of graft-versus-host disease. Semin Hematol 2006, 43:3-10.
336. Snover DC Acute and chronic graft versus host disease: Histopathological evidence for two distinct pathogenetic mechanisms. Hum Pathol 1984, 15:202-205.
337. Horwitz ME, Sullivan KM Chronic graft-versus-host disease. Blood Rev 2006, 20:15-27.
338. Snover D Acute and chronic graft-versus-host disease. Graft-versus-Host Disease: Immunology, Pathophysiology, and Treatment 1990, 337-9647. Marcel Dekker, New York. S. Burakoff, H. Geeg, J. Ferrara, K. Atkinson (Eds.).
339. Shulman HM Pathology of chronic graft-vs.-host disease. Graft-versus-Host Disease: Immunology, Pathophysiology, and Treatment 1990, 587-9386. Marcel Dekker, New York. S. Burakoff, H. Geeg, J. Ferrara, K. Atkinson (Eds.).
340. Snover DC, Weisdorf SA, Ramsay NK, et al. Hepatic graft versus host disease: A study of the predictive value of liver biopsy in diagnosis. Hepatology 1984, 4:123-130.
341. Shulman HM, Sharma P, Amos D, et al. A coded histologic study of hepatic graft-versus-host disease after human bone marrow transplantation. Hepatology 1988, 8:463-470.
342. Quaglia A, Duarte R, Patch D, et al. Histopathology of graft versus host disease of the liver. Histopathology 2007, 50:727-738.
343. Tanaka M, Umihara J, Shimmoto K, et al. The pathogenesis of graft-versus-host reaction in the intrahepatic bile duct: An immunohistochemical study. Acta Pathol Jpn 1989, 39:648-655.
344. Bach N, Thung SN, Schaffner F The histological features of chronic hepatitis C and autoimmune chronic hepatitis: A comparative analysis. Hepatology 1992, 15:572-577.
345. Vierling JM Immune disorders of the liver and bile duct. Gastroenterol Clin North Am 1992, 21:427-449.
346. Andersen CB, Horn T, Sehested M, et al. Graft-versus-host disease: Liver morphology and pheno/genotypes of inflammatory cells and target cells in sex-mismatched allogeneic bone marrow transplant patients. Transplant Proc 1993, 25:1250-1254.
347. Yeh KH, Hsieh HC, Tang JL, et al. Severe isolated acute hepatic graft-versus-host disease with vanishing bile duct syndrome. Bone Marrow Transplant 1994, 14:319-321.
348. Yau JC, Zander AR, Srigley JR, et al. Chronic graft-versus-host disease complicated by micronodular cirrhosis and esophageal varices. Transplantation 1986, 41:129-130.
349. Knapp AB, Crawford JM, Rappeport JM, Gollan JL Cirrhosis as a consequence of graft-versus-host disease. Gastroenterology 1987, 92:513-519.
350. Stechschulte DJ, Fishback JL, Emami A, Bhatia P Secondary biliary cirrhosis as a consequence of graft-versus-host disease. Gastroenterology 1990, 98:223-225.
351. Urban CH, Deutschmann A, Kerbl R, et al. Organ tolerance following cadaveric liver transplantation for chronic graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant 2002, 30:535-537.
352. Strasser SI, Shulman HM, Flowers ME, et al. Chronic graft-versus-host disease of the liver: Presentation as an acute hepatitis. Hepatology 2000, 32:1265-1271.
353. Fujii N, Takenaka K, Shinagawa K, et al. Hepatic graft-versus-host disease presenting as an acute hepatitis after allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2001, 27:1007-1010.
354. Akpek G, Boitnott JK, Lee LA, et al. Hepatitic variant of graft-versus-host disease after donor lymphocyte infusion. Blood 2002, 100:3903-3907.
355. Malik AH, Collins RH, Saboorian MH, Lee WM Chronic graft-versus-host disease after hematopoietic cell transplantation presenting as an acute hepatitis. Am J Gastroenterol 2001, 96:588-590.
356. Ma SY, Au WY, Ng IOL, et al. Hepatitic graft-versus-host disease after hematopoietic stem cell transplantation: Clinicopathologic features and prognostic implication. Transplantation 2004, 77:1252-1259.
357. Duarte RF, Delgado J, Shaw B, et al. Histologic features of the liver biopsy predict the clinical outcome for patients with graft-versus-host disease of the liver. Biol Blood Marrow Transpl 2005, 11:805-813.
358. Picardi M, De Rosa G, Muretto P, et al. Ultrasound-guided fine needle cutting biopsy for the characterization of diffuse liver diseases in bone marrow transplant patients. Bone Marrow Transplant 1998, 22:571-573.
359. Iqbal M, Creger RJ, Fox RM, et al. Laparoscopic liver biopsy to evaluate hepatic dysfunction in patients with hematologic malignancies: A useful tool to effect changes in management. Bone Marrow Transplant 1996, 17:655-662.
360. Naber AH, Van Haelst U, Yap SH Nodular regenerative hyperplasia of the liver: An important cause of portal hypertension in non-cirrhotic patients. J Hepatol 1991, 12:94-99.
361. Snover DC, Weisdorf S, Bloomer J, et al. Nodular regenerative hyperplasia of the liver following bone marrow transplantation. Hepatology 1989, 9:443-448.
362. Morales JM, Prieto C, Colina F, et al. Nodular regenerative hyperplasia of the liver in renal transplantation. Transplant Proc 1987, 19:3694-3696.
363. Stromeyer FW, Ishak KG Nodular transformation (nodular "regenerative" hyperplasia) of the liver: A clinicopathologic study of 30 cases. Hum Pathol 1981, 12:60-71.
364. Crawford JM, Boyer JL Clinicopathology conferences: Inflammation-induced cholestasis. Hepatology 1998, 28:253-260.
365. Norris SH, Butler TC, Glass N, Tran R Fatal hepatic necrosis caused by disseminated type 5 adenovirus infection in a renal transplant recipient. Am J Nephrol 1989, 9:101-105.
366. Ludwig J, Batts K Transplantation pathology. Pathology of the Liver 1994, 766-9214. Churchill Livingstone, Edinburgh. 3rd ed. R. MacSween, P. Anthony, P. Scheuer (Eds.).
367. Fairley CK, Mijch A, Gust ID, et al. The increased risk of fatal liver disease in renal transplant patients who are hepatitis Be antigen and/or HBV DNA positive. Transplantation 1991, 52:497-500.
368. Fornairon S, Pol S, Legendre C, et al. The long-term virologic and pathologic impact of renal transplantation on chronic hepatitis B virus infection. Transplantation 1996, 62:297-299.
369. Roth D Hepatitis C virus infection and the renal allograft recipient. Nephron 1995, 71:249-253.
370. Brunson ME, Lau JY, Davis GL, et al. Non-A, non-B hepatitis and elevated serum aminotransferases in renal transplant patients: Correlation with hepatitis C infection. Transplantation 1993, 56:1364-1367.
371. Lim HL, Lau GK, Davis GL, et al. Cholestatic hepatitis leading to hepatic failure in a patient with organ-transmitted hepatitis C virus infection. Gastroenterology 1994, 106:248-251.
372. Delladetsima JK, Boletis JN, Makris F, et al. Fibrosing cholestatic hepatitis in renal transplant recipients with hepatitis C virus infection. Liver Transpl Surg 1999, 5:294-300.
373. Munoz de Bustillo E, Benito A, et al. Fibrosing cholestatic hepatitis-like syndrome in hepatitis B virus-negative and hepatitis C virus-negative renal transplant recipients. Am J Kidney Dis 2001, 38:640-645.
374. Gulbahce HE, Brown CA, Wick M, et al. Graft-versus-host disease after solid organ transplant. Am J Clin Pathol 2003, 119:568-573.
375. McCaughan GW, Torzillo PJ Hepatitis A, liver transplants and indigenous communities. Med J Aust 2000, 172:6-7.
376. Douglas DD, Rakela J, Wright TL, et al. The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient. Liver Transpl Surg 1997, 3:105-111.
377. Muller R, Gubernatis G, Farle M, et al. Liver transplantation in HBs antigen (HBsAg) carriers: Prevention of hepatitis B virus (HBV) recurrence by passive immunization. J Hepatol 1991, 13:90-96.
378. Konig V, Hopf U, Neuhaus P, et al. Long-term follow-up of hepatitis B virus-infected recipients after orthotopic liver transplantation. Transplantation 1994, 58:553-559.
379. Tchervenkov JI, Tector AJ, Barkun JS, et al. Recurrence-free long-term survival after liver transplantation for hepatitis B using interferon-alpha pretransplant and hepatitis B immune globulin posttransplant. Ann Surg 1997, 226:356-365.
380. Angus PW Review: Hepatitis B and liver transplantation. J Gastroenterol Hepatol 1997, 12:217-223.
381. Roche B, Samuel D, Feray C, et al. Retransplantation of the liver for recurrent hepatitis B virus infection: The Paul Brousse experience. Liver Transpl Surg 1999, 5:166-174.
382. Cane PA, Mutimer D, Ratcliffe D, et al. Analysis of hepatitis B virus quasispecies changes during emergence and reversion of lamivudine resistance in liver transplantation. Antivir Ther 1999, 4:7-14.
383. Rayes N, Seehofer D, Bechstein WO, et al. Long-term results of famciclovir for recurrent or de novo hepatitis B virus infection after liver transplantation. Clin Transplant 1999, 13:447-452.
384. Roche B, Samuel D, Gigou M, et al. Long-term ganciclovir therapy for hepatitis B virus infection after liver transplantation. J Hepatol 1999, 31:584-592.
385. Mutimer D, Pillay D, Shields P, et al. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient. Gut 2000, 46:107-113.
386. Seehofer D, Rayes N, Neuhaus R, et al. Antiviral combination therapy for lamivudine-resistant hepatitis B reinfection after liver transplantation. Transpl Int 2000, 13(Suppl 1):S359-S362.
387. Gutfreund KS, Williams M, George R, et al. Genotypic succession of mutations of the hepatitis B virus polymerase associated with lamivudine resistance. J Hepatol 2000, 33:469-475.
388. Seehofer D, Rayes N, Steinmuller T, et al. Occurrence and clinical outcome of lamivudine-resistant hepatitis B infection after liver transplantation. Liver Transpl 2001, 7:976-982.
389. Walsh KM, Woodall T, Lamy P, et al. Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus. Gut 2001, 49:436-440.
390. Castells L, Esteban R Hepatitis B vaccination in liver transplant candidates. Eur J Gastroenterol Hepatol 2001, 13:359-361.
391. Ben-Ari Z, Mor E, Shapira Z, Tur-Kaspa R Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation. Liver Transpl 2001, 7:113-117.
392. Bock CT, Tillmann HL, Torresi J, et al. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 2002, 122:264-273.
393. Gane EJ, Portmann BC, Naoumov NV, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996, 334:815-820.
394. Chazouilleres O, Kim M, Combs C, et al. Quantitation of hepatitis C virus RNA in liver transplant recipients. Gastroenterology 1994, 106:994-999.
395. McCaughan GW, Zekry A Impact of immunosuppression on immunopathogenesis of liver damage in hepatitis C virus-infected recipients following liver transplantation. Liver Transpl 2003, 9:S21-S27.
396. Rosen HR Hepatitis C virus in the human liver transplantation model. Clin Liver Dis 2003, 7:107-125.
397. Sanchez-Fueyo A, Restrepo JC, Quinto L, et al. Impact of the recurrence of hepatitis C virus infection after liver transplantation on the long-term viability of the graft. Transplantation 2002, 73:56-63.
398. Bernard PH, Le Bail B, Rullier A, et al. Recurrence and accelerated progression of hepatitis C following liver transplantation. Semin Liver Dis 2000, 20:533-538.
399. Charlton M Natural history of hepatitis C and outcomes following liver transplantation. Clin Liver Dis 2003, 7:585-602.
400. Wiesner RH, Sorrell M, Villamil F Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003, 9:S1-S9.
401. Caccamo L, Gridelli B, Sampietro M, et al. Hepatitis C virus genotypes and reinfection of the graft during long-term follow-up in 35 liver transplant recipients. Transpl Int 1996, 9(Suppl 1):S204-S209.
402. Gordon FD, Poterucha JJ, Germer J, et al. Relationship between hepatitis C genotype and severity of recurrent hepatitis C after liver transplantation. Transplantation 1997, 63:1419-1423.
403. Gigou M, Roque-Afonso AM, Falissard B, et al. Genetic clustering of hepatitis C virus strains and severity of recurrent hepatitis after liver transplantation. J Virol 2001, 75:11292-11297.
404. Charlton M, Seaberg E, Wiesner R, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998, 28:823-830.
405. Zhou S, Terrault NA, Ferrell L, et al. Severity of liver disease in liver transplantation recipients with hepatitis C virus infection: Relationship to genotype and level of viremia. Hepatology 1996, 24:1041-1046.
406. Guido M, Fagiuoli S, Tessari G, et al. Histology predicts cirrhotic evolution of post transplant hepatitis C. Gut 2002, 50:697-700.
407. Neuberger J, Portmann B, Calne R, Williams R Recurrence of autoimmune chronic active hepatitis following orthotopic liver grafting. Transplantation 1984, 37:363-365.
408. Sempoux C, Horsmans Y, Lerut J, et al. Acute lobular hepatitis as the first manifestation of recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver 1997, 17:311-315.
409. Prados E, Cuervas-Mons V, de la Mata M, et al. Outcome of autoimmune hepatitis after liver transplantation. Transplantation 1998, 66:1645-1650.
410. Ayata G, Gordon FD, Lewis WD, et al. Liver transplantation for autoimmune hepatitis: A long-term pathologic study. Hepatology 2000, 32:185-192.
411. Gonzalez-Koch A, Czaja AJ, Carpenter HA, et al. Recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver Transpl 2001, 7:302-310.
412. Wright HL, Bou-Abboud CF, Hassanein T, et al. Disease recurrence and rejection following liver transplantation for autoimmune chronic active liver disease. Transplantation 1992, 53:136-139.
413. Czaja AJ, Strettell MD, Thomson LJ, et al. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. Hepatology 1997, 25:317-323.
414. Birnbaum AH, Benkov KJ, Pittman NS, et al. Recurrence of autoimmune hepatitis in children after liver transplantation. J Pediatr Gastroenterol Nutr 1997, 25:20-25.
415. Faust TW Recurrent primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis after transplantation. Semin Liver Dis 2000, 20:481-495.
416. McDiarmid SV Liver transplantation: The pediatric challenge. Clin Liver Dis 2000, 4:879-927.
417. Neuberger J, Portmann B, Macdougall BR, et al. Recurrence of primary biliary cirrhosis after liver transplantation. N Engl J Med 1982, 306:1-4.
418. Balan V, Batts KP, Porayko MK, et al. Histological evidence for recurrence of primary biliary cirrhosis after liver transplantation. Hepatology 1993, 18:1392-1398.
419. Polson RJ, Portmann B, Neuberger J, et al. Evidence for disease recurrence after liver transplantation for primary biliary cirrhosis: Clinical and histologic follow-up studies. Gastroenterology 1989, 97:715-725.
420. Esquivel CO, Van Thiel DH, Demetris AJ, et al. Transplantation for primary biliary cirrhosis. Gastroenterology 1988, 94:1207-1216.
421. Demetris AJ, Markus BH, Esquivel C, et al. Pathologic analysis of liver transplantation for primary biliary cirrhosis. Hepatology 1988, 8:939-947.
422. Sanchez-Urdazpal L, Czaja AJ, van Hoek B, et al. Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. Hepatology 1992, 15:215-221.
423. Jaeckel E, Tillmann HL, Manns MP Liver transplantation and autoimmunity. Acta Gastroenterol Belg 1999, 62:323-329.
424. Tan CK, Sian Ho JM Concurrent de novo autoimmune hepatitis and recurrence of primary biliary cirrhosis post-liver transplantation. Liver Transpl 2001, 7:461-465.
425. Graziadei IW Recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 2002, 8:575-581.
426. Khettry U, Keaveny A, Goldar-Najafi A, et al. Liver transplantation for primary sclerosing cholangitis: A long-term clinicopathologic study. Hum Pathol 2003, 34:1127-1136.
427. Vera A, Moledina S, Gunson B, et al. Risk factors for recurrence of primary sclerosing cholangitis of liver allograft. Lancet 2002, 360:1943-1944.
428. Graziadei IW, Wiesner RH, Batts KP, et al. Recurrence of primary sclerosing cholangitis following liver transplantation. Hepatology 1999, 29:1050-1056.
429. Anand AC, Hubscher SG, Gunson BK, et al. Timing, significance, and prognosis of late acute liver allograft rejection. Transplantation 1995, 60:1098-1103.
430. Yoshida EM, Shackleton CR, Erb SR, et al. Late acute rejection occurring in liver allograft recipients. Can J Gastroenterol 1996, 10:376-380.
431. D'Antiga L, Dhawan A, Portmann B, et al. Late cellular rejection in paediatric liver transplantation: Aetiology and outcome. Transplantation 2002, 73:80-84.
432. Neil DA, Hubscher SG Delay in diagnosis: A factor in the poor outcome of late acute rejection of liver allografts. Transplant Proc 2001, 33:1525-1526.
433. Lowes JR, Hubscher SG, Neuberger JM Chronic rejection of the liver allograft. Gastroenterol Clin North Am 1993, 22:401-420.
434. Hoek BV, Wiesner R, Krom R, et al. Severe ductopenic rejection following liver transplantation: Incidence, time of onset, risk factors, treatment and outcome. Semin Liver Dis 1992, 12:41-50.
435. Ludwig J, Wiesner RH, Batts KP, et al. The acute vanishing bile duct syndrome (acute irreversible rejection) after orthotopic liver transplantation. Hepatology 1987, 7:476-483.
436. Fennell RH Ductular damage in liver transplant rejection: Its similarity to that of primary biliary cirrhosis and graft-versus-host disease. Pathol Annu 1981, 16:289-294.
437. Grond J, Gouw AS, Poppema S, et al. Chronic rejection in liver transplants: A histopathologic analysis of failed grafts and antecedent serial biopsies. Transplant Proc 1986, 18:128-135.
438. Vierling JM, Fennell RH Histopathology of early and late human hepatic allograft rejection: Evidence of progressive destruction of interlobular bile ducts. Hepatology 1985, 5:1076-1082.
439. Portmann B, Neuberger J, Williams R Intrahepatic bile duct lesions. Liver Transplantation: The Cambridge-Kings College Hospital Experience 1983, 279-9713. Grune and Stratton, New York. R. Calne (Ed.).
440. Wight DA Chronic liver transplant rejection: Definition and diagnosis. Transplant Proc 1996, 28:465-467.
441. Quiroga J, Colina I, Demetris AJ, et al. Cause and timing of first allograft failure in orthotopic liver transplantation: A study of 177 consecutive patients. Hepatology 1991, 14:1054-1062.
442. Starzl TE, Marchioro TL, Porter KA Experimental and clinical observations after homotransplantation of the whole liver. Rev Int Hepatol 1965, 15:1447-1480.
443. Porte RJ, Ploeg RJ, Hansen B, et al. Long-term graft survival after liver transplantation in the UW era: Late effects of cold ischemia and primary dysfunction. European Multicentre Study Group. Transpl Int 1998, 11(Suppl 1):S164-S167.
444. Nakhleh RE, Schwarzenberg SJ, Bloomer J, et al. The pathology of liver allografts surviving longer than one year. Hepatology 1990, 11:465-470.
445. Evans HM, Kelly DA, McKiernan PJ, Hübscher SG Progressive histological damage in liver allografts following paediatric liver transplantation. Hepatology 2006, 43:1109-1117.
446. Kim WR, Poterucha JJ, Porayko MK, et al. Recurrence of nonalcoholic steatohepatitis following liver transplantation. Transplantation 1996, 62:1802-1805.
447. Contos MJ, Cales W, Sterling RK, et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl 2001, 7:363-373.
448. Charlton M, Kasparova P, Weston S, et al. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transpl 2001, 7:608-614.
449. Wong LL Current status of liver transplantation for hepatocellular cancer. Am J Surg 2002, 183:309-316.
450. Figueras J, Ibanez L, Ramos E, et al. Selection criteria for liver transplantation in early-stage hepatocellular carcinoma with cirrhosis: Results of a multicenter study. Liver Transpl 2001, 7:877-883.
451. Frilling A, Malago M, Broelsch CE Current status of liver transplantation for treatment of hepatocellular carcinoma. Dig Dis 2001, 19:333-337.
452. Iwatsuki S, Dvorchik I, Marsh JW, et al. Liver transplantation for hepatocellular carcinoma: A proposal of a prognostic scoring system. J Am Coll Surg 2000, 191:389-394.
453. Klintmalm GB Liver transplantation for hepatocellular carcinoma: A registry report of the impact of tumor characteristics on outcome. Ann Surg 1998, 228:479-490.
454. Marsh JW, Casavilla A, Iwatsuki S, et al. Predicting the risk of tumor recurrence following transplantation for hepatocellular carcinoma. Hepatology 1997, 26:1689-1691.
455. Tamura S, Kato T, Berho M, et al. Impact of histological grade of hepatocellular carcinoma on the outcome of liver transplantation. Arch Surg 2001, 136:25-30.
456. Casavilla FA, Marsh JW, Iwatsuki S, et al. Hepatic resection and transplantation for peripheral cholangiocarcinoma. J Am Coll Surg 1997, 185:429-436.
457. Iwatsuki S, Todo S, Marsh JW, et al. Treatment of hilar cho-langiocarcinoma (Klatskin tumors) with hepatic resection or transplantation. J Am Coll Surg 1998, 187:358-364.
458. Meyer CG, Penn I, James L Liver transplantation for cho-langiocarcinoma: Results in 207 patients. Transplantation 2000, 69:1633-1637.
459. Weimann A, Varnholt H, Schlitt HJ, et al. Retrospective analysis of prognostic factors after liver resection and transplantation for cholangiocellular carcinoma. Br J Surg 2000, 87:1182-1187.
460. Starzl T Surgery for metabolic liver disease. Surgery of the Liver 1986, 127-9864. Blackwell Scientific Publications, Boston. M. WV (Ed.).
461. Putnam CW, Porter KA, Peters RL, et al. Liver replacement for alpha1-antitrypsin deficiency. Surgery 1977, 81:258-261.
462. DuBois RS, Rodgerson DO, Martineau G, et al. Orthotopic liver transplantation for Wilson's disease. Lancet 1971, 1:505-508.
463. Groth CG, Dubois RS, Corman J, et al. Metabolic effects of hepatic replacement in Wilson's disease. Transplant Proc 1973, 5:829-833.
464. Zitelli BJ, Malatack JJ, Gartner JC, et al. Orthotopic liver transplantation in children with hepatic-based metabolic disease. Transplant Proc 1983, 15:1284-1287.
465. Fisch RO, McCabe ER, Doeden D, et al. Homotransplantation of the liver in a patient with hepatoma and hereditary tyrosinemia. J Pediatr 1978, 93:592-596.
466. Starzl TE, Zitelli BJ, Shaw BW, et al. Changing concepts: Liver replacement for hereditary tyrosinemia and hepatoma. J Pediatr 1985, 106:604-606.
467. Malatack JJ, Finegold DN, Iwatsuki S, et al. Liver transplantation for type I glycogen storage disease. Lancet 1983, 1:1073-1075.
468. Matern D, Starzl TE, Arnaout W, et al. Liver transplantation for glycogen storage disease types I, III, and IV. Eur J Pediatr 1999, 158(Suppl 2):S43-S48.
469. Kayler LK, Merion RM, Lee S, et al. Long-term survival after liver transplantation in children with metabolic disorders. Pediatr Transplant 2002, 6:295-300.
470. Figueras J, Pares D, Munar-Ques M, et al. Experience with domino or sequential liver transplantation in familial patients with amyloid polyneuropathy. Transplant Proc 2002, 34:307-308.
471. Shaz BH, Lewis WD, Skinner M, Khettry U Livers from patients with apolipoprotein A-I amyloidosis are not suitable as "domino" donors. Mod Pathol 2001, 14:577-580.
472. Nishizaki T, Kishikawa K, Yoshizumi T, et al. Domino liver transplantation from a living related donor. Transplantation 2000, 70:1236-1239.
473. de Carvalho M, Conceicao I, Bentes C, Luis ML Long-term quantitative evaluation of liver transplantation in familial amyloid polyneuropathy (Portuguese V30M). Amyloid 2002, 9:126-133.
474. Suhr OB, Ericzon BG, Friman S Long-term follow-up of survival of liver transplant recipients with familial amyloid polyneuropathy (Portuguese type). Liver Transpl 2002, 8:787-794.
475. Wolff H, Otto G, Giest H Liver transplantation in Crigler-Najjar syndrome: A case report. Transplantation 1986, 42:84.
476. Kaufman SS, Wood RP, Shaw BW, et al. Orthotopic liver transplantation for type I Crigler-Najjar syndrome. Hepatology 1986, 6:1259-1262.
477. Shneider BL Pediatric liver transplantation in metabolic disease: Clinical decision making. Pediatr Transplant 2002, 6:25-29.
478. Casella JF, Lewis JH, Bontempo FA, et al. Successful treatment of homozygous protein C deficiency by hepatic transplantation. Lancet 1988, 1:435-438.
479. Starzl TE, Bilheimer DW, Bahnson HT, et al. Heart-liver transplantation in a patient with familial hypercholesterol-aemia. Lancet 1984, 1:1382-1383.
480. Lewis JH, Bontempo FA, Spero JA, et al. Liver transplantation in a hemophiliac. N Engl J Med 1985, 312:1189-1190.
481. Bontempo FA, Lewis JH, Gorenc TJ, et al. Liver transplantation in hemophilia A. Blood 1987, 69:1721-1724.
482. Merion RM, Delius RE, Campbell DA, Turcotte JG Orthotopic liver transplantation totally corrects factor IX deficiency in hemophilia B. Surgery 1988, 104:929-931.
483. Brandhagen DJ Liver transplantation for hereditary hemochromatosis. Liver Transpl 2001, 7:663-672.
484. Brandhagen DJ, Alvarez W, Therneau TM, et al. Iron overload in cirrhosis-HFE genotypes and outcome after liver transplantation. Hepatology 2000, 31:456-460.
485. Daloze P, Delvin EE, Glorieux FH, et al. Replacement therapy for inherited enzyme deficiency: Liver orthotopic transplantation in Niemann-Pick disease type A. Am J Med Genet 1977, 1:229-239.
486. Gartner JC, Bergman I, Malatack JJ, et al. Progression of neurovisceral storage disease with supranuclear ophthalmoplegia following orthotopic liver transplantation. Pediatrics 1986, 77:104-106.
487. Samuel D, Boboc B, Bernuau J, et al. Liver transplantation for protoporphyria: Evidence for the predominant role of the erythropoietic tissue in protoporphyrin overproduction. Gastroenterology 1988, 95:816-819.
488. de Torres I, Demetris AJ, Randhawa PS Recurrent hepatic allograft injury in erythropoietic protoporphyria. Transplantation 1996, 61:1412-1413.
489. Dellon ES, Szczepiorkowski ZM, Dzik WH, et al. Treatment of recurrent allograft dysfunction with intravenous hematin after liver transplantation for erythropoietic protoporphyria. Transplantation 2002, 73:911-915.
490. Cox KL, Ward RE, Furgiuele TL, et al. Orthotopic liver transplantation in patients with cystic fibrosis. Pediatrics 1987, 80:571-574.
491. Mieles LA, Orenstein D, Teperman L, et al. Liver transplantation in cystic fibrosis. Lancet 1989, 1:1073.
492. Milkiewicz P, Skiba G, Kelly D, et al. Transplantation for cystic fibrosis: Outcome following early liver transplantation. J Gastroenterol Hepatol 2002, 17:208-213.
493. Pappo O, Ramos H, Starzl TE, et al. Structural integrity and identification of causes of liver allograft dysfunction occurring more than 5 years after transplantation. Am J Surg Pathol 1995, 19:192-206.
494. Heneghan MA, Zolfino T, Muiesan P, et al. An evaluation of long-term outcomes after liver transplantation for cryptogenic cirrhosis. Liver Transpl 2003, 9:921-928.
495. Maor-Kendler Y, Batts KP, Burgart LJ, et al. Comparative allograft histology after liver transplantation for cryptogenic cirrhosis, alcohol, hepatitis C, and cholestatic liver diseases. Transplantation 2000, 70:292-297.